Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2003 2
2004 4
2005 1
2007 1
2009 4
2011 1
2012 1
2013 3
2014 3
2015 3
2016 1
2017 3
2018 2
2019 2
2021 2
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Locally Advanced Chordoma"
Page 1
Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSe Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial.
Blay JY, Chevret S, Le Cesne A, Brahmi M, Penel N, Cousin S, Bertucci F, Bompas E, Ryckewaert T, Soibinet P, Boudou-Rouquette P, Saada Bouzid E, Soulie P, Valentin T, Lotz JP, Tosi D, Neviere Z, Cancel M, Ray-Coquard I, Gambotti L, Legrand F, Lamrani-Ghaouti A, Simon C, Even C, Massard C. Blay JY, et al. Lancet Oncol. 2023 Aug;24(8):892-902. doi: 10.1016/S1470-2045(23)00282-6. Epub 2023 Jul 7. Lancet Oncol. 2023. PMID: 37429302 Clinical Trial.
Key inclusion criteria were age 15 years or older, Eastern Cooperative Oncology Group performance status of 0-1, and advanced disease that was untreated and resistant to treatment. Patients were given pembrolizumab 200 mg intravenously on day 1 of every 21-day cycle for a …
Key inclusion criteria were age 15 years or older, Eastern Cooperative Oncology Group performance status of 0-1, and advanced disease …
Medical treatment of advanced chordomas.
Colia V, Stacchiotti S. Colia V, et al. Eur J Cancer. 2017 Sep;83:220-228. doi: 10.1016/j.ejca.2017.06.038. Epub 2017 Jul 25. Eur J Cancer. 2017. PMID: 28750274 Review.
Patients carrying an advanced disease need a systemic treatment. Unluckily, conventional chordoma are insensitive to cytotoxic chemotherapy that is considered the standard treatment option in patients with metastatic sarcoma. ...In addition, a better understanding o …
Patients carrying an advanced disease need a systemic treatment. Unluckily, conventional chordoma are insensitive to cytotoxic …
Proton therapy for sarcomas.
Keole S, Ashman JB, Daniels TB. Keole S, et al. Cancer J. 2014 Nov-Dec;20(6):409-14. doi: 10.1097/PPO.0000000000000084. Cancer J. 2014. PMID: 25415687 Review.
Sarcomas are a heterogeneous group of tumors that can occur in a wide array of anatomic sites and age ranges with varying histologies. Proton beam therapy, as compared with advanced x-ray radiation therapy techniques, can substantially lower dose to nontarget tissues. ...T …
Sarcomas are a heterogeneous group of tumors that can occur in a wide array of anatomic sites and age ranges with varying histologies. Proto …
Chordoma: current concepts, management, and future directions.
Walcott BP, Nahed BV, Mohyeldin A, Coumans JV, Kahle KT, Ferreira MJ. Walcott BP, et al. Lancet Oncol. 2012 Feb;13(2):e69-76. doi: 10.1016/S1470-2045(11)70337-0. Lancet Oncol. 2012. PMID: 22300861 Review.
Chordoma is a rare bone cancer that is aggressive, locally invasive, and has a poor prognosis. ...In this Review, we highlight current standards in diagnosis, clinical management, and molecular characterisation of chordomas, and discuss current researc …
Chordoma is a rare bone cancer that is aggressive, locally invasive, and has a poor prognosis. ...In this Review, we highlight …
Molecular targeted therapies in advanced or metastatic chordoma patients: facts and hypotheses.
Lebellec L, Aubert S, Zaïri F, Ryckewaert T, Chauffert B, Penel N. Lebellec L, et al. Crit Rev Oncol Hematol. 2015 Jul;95(1):125-31. doi: 10.1016/j.critrevonc.2015.01.010. Epub 2015 Jan 30. Crit Rev Oncol Hematol. 2015. PMID: 25682222 Review.
Despite surgery followed by radiotherapy, local and metastatic relapses are frequent. In case of locally advanced or metastatic chordomas, medical treatment is frequently discussed. ...A systematic analysis of these publications shows that the best obj …
Despite surgery followed by radiotherapy, local and metastatic relapses are frequent. In case of locally advanced or me …
Proton therapy in chordoma of the base of the skull: a systematic review.
Amichetti M, Cianchetti M, Amelio D, Enrici RM, Minniti G. Amichetti M, et al. Neurosurg Rev. 2009 Oct;32(4):403-16. doi: 10.1007/s10143-009-0194-4. Epub 2009 Mar 25. Neurosurg Rev. 2009. PMID: 19319583 Review.
Chordoma is a rare, slow-growing, locally aggressive, primary bone tumor that arises from the skull base region in approximately 25-35% of cases. ...According to the inclusion criteria, 47 articles were considered in the analysis. There were no prospective trials ( …
Chordoma is a rare, slow-growing, locally aggressive, primary bone tumor that arises from the skull base region in approximate …
Chordoma: a case series and review of the literature.
Alan O, Akin Telli T, Ercelep O, Tanrikulu Simsek E, Basoglu Tuylu T, Mutis A, Hasanov R, Kaya S, Akgül Babacan N, Dane F, Yumuk PF. Alan O, et al. J Med Case Rep. 2018 Aug 27;12(1):239. doi: 10.1186/s13256-018-1784-y. J Med Case Rep. 2018. PMID: 30145982 Free PMC article. Review.
Patients with advanced chordoma have a poor prognosis due to locoregional recurrence with infiltration and destruction of surrounding bone and soft tissue. ...Randomized trials with large patient numbers are unfeasible in this rare disease. ...
Patients with advanced chordoma have a poor prognosis due to locoregional recurrence with infiltration and destruction of surr …
The evolution of systemic therapy in sarcoma.
Constantinidou A, Pollack S, Loggers E, Rodler E, Jones RL. Constantinidou A, et al. Expert Rev Anticancer Ther. 2013 Feb;13(2):211-23. doi: 10.1586/era.12.161. Expert Rev Anticancer Ther. 2013. PMID: 23406562 Review.
Approximately 50% of patients with localized soft tissue sarcomas will develop recurrent disease after complete surgical resection, requiring alternative means of treatment. ...Some histological subtypes are resistant to conventional chemotherapy and patients with these di …
Approximately 50% of patients with localized soft tissue sarcomas will develop recurrent disease after complete surgical resection, r …
Imatinib mesylate in chordoma.
Casali PG, Messina A, Stacchiotti S, Tamborini E, Crippa F, Gronchi A, Orlandi R, Ripamonti C, Spreafico C, Bertieri R, Bertulli R, Colecchia M, Fumagalli E, Greco A, Grosso F, Olmi P, Pierotti MA, Pilotti S. Casali PG, et al. Cancer. 2004 Nov 1;101(9):2086-97. doi: 10.1002/cncr.20618. Cancer. 2004. PMID: 15372471 Free article.
METHODS: Six patients with advanced chordoma were treated with imatinib mesylate at a dose of 800 mg daily. ...The benefit to the patient entailed by this pattern of tumor response in chordoma needs to be elucidated, but may be limited in the presence of sign …
METHODS: Six patients with advanced chordoma were treated with imatinib mesylate at a dose of 800 mg daily. ...The benefit to …
Systematic assessment of clinical outcomes and toxicities of proton radiotherapy for reirradiation.
Verma V, Rwigema JM, Malyapa RS, Regine WF, Simone CB 2nd. Verma V, et al. Radiother Oncol. 2017 Oct;125(1):21-30. doi: 10.1016/j.radonc.2017.08.005. Epub 2017 Sep 20. Radiother Oncol. 2017. PMID: 28941560 Review.
PBT for recurrent uveal melanoma achieved 5-year eye retention of 55%; for chordomas, reRT afforded a 2-year local control and overall survival (OS) of 85% and 80%, respectively. ...Institutional experiences must continue to be reported: dosimetric correlations, lat …
PBT for recurrent uveal melanoma achieved 5-year eye retention of 55%; for chordomas, reRT afforded a 2-year local control and …
37 results